| Filed On | Filing |
|---|---|
| 04 Nov 2025 |
8-K/A: Results of Operations and Financial Condition
SALT LAKE CITY, November 3, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2025 and reaffirmed its... |
| 07 Feb 2020 |
8-K/A: Results of Operations and Financial Condition; Regulation FD Disclosure
SALT LAKE CITY, Feb. 6, 2020 – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced financial results for its fiscal second-quarter 2020, provid... |
| 15 Oct 2018 |
8-K/A: Completion of Acquisition or Disposition of Assets
We have audited the accompanying consolidated balance sheet of Counsyl, Inc. and its subsidiary as of December 31, 2017, and the related consolidated statements of operations and comprehensive loss, of redeemable convertible preferred st... |
| 14 Nov 2016 |
8-K/A: Completion of Acquisition or Disposition of Assets
We have audited the accompanying consolidated balance sheets of Assurex Health, Inc. and Subsidiary as of December 31, 2014 and 2015, and the related consolidated statements of operations and comprehensive loss, redeemable convertible pr... |
| 09 May 2014 |
8-K/A: Completion of Acquisition or Disposition of Assets
We have audited the accompanying financial statements of Crescendo Bioscience, Inc. (the Company) which comprise the balance sheet as of December 31, 2013, and the related statements of operations and comprehensive loss, changes in conve... |
| 06 Feb 2007 |
8-K/A: Results of Operations and Financial Condition; Other Events
Salt Lake City, February 6, 2007 — Myriad Genetics, Inc. (Nasdaq: MYGN) today reported financial results for the second quarter of fiscal 2007 and the six months ended December 31, 2006. |
Loading...